Selected research
Industry Research
Preclinical Assets Industry Research Report 2026
Market perspective
The global Preclinical Assets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Preclinical Assets market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Preclinical Assets market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Preclinical Assets market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Preclinical Assets include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Preclinical Assets market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Preclinical Assets.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Preclinical Assets Market by Company
Eurofins Scientific
Viroclinics Xplore
SGS
Intertek Group
AmplifyBio
IQVIA
ICON plc
Medpace
Pharmatest Services
PPD
Crown Bioscience
Comparative Biosciences
TCG Lifesciences
Domainex
Absorption Systems
Preclinical Assets Segment by Type
Bioanalysis and DMPK Studies
Toxicology Testing
Compound Management
Safety Pharmacology
Others
Preclinical Assets Segment by Application
Biopharmaceutical Companies
Government Institutes
Research institutes
Others
Preclinical Assets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Assets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Preclinical Assets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Assets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Preclinical Assets companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bioanalysis and DMPK Studies
- Toxicology Testing
- Compound Management
- Safety Pharmacology
- Others
Applications
- Biopharmaceutical Companies
- Government Institutes
- Research institutes
- Others
Companies covered
- Eurofins Scientific
- Viroclinics Xplore
- SGS
- Intertek Group
- AmplifyBio
- IQVIA
- ICON plc
- Medpace
- Pharmatest Services
- PPD
- Crown Bioscience
- Comparative Biosciences
- TCG Lifesciences
- Domainex
- Absorption Systems
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Preclinical Assets by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Bioanalysis and DMPK Studies
- 2.2.3 Toxicology Testing
- 2.2.4 Compound Management
- 2.2.5 Safety Pharmacology
- 2.2.6 Others
- 2.3 Preclinical Assets by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biopharmaceutical Companies
- 2.3.3 Government Institutes
- 2.3.4 Research institutes
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Preclinical Assets Breakdown Data by Type
- 3.1 Global Preclinical Assets Historic Market Size by Type (2021-2026)
- 3.2 Global Preclinical Assets Forecasted Market Size by Type (2027-2032)
4 Preclinical Assets Breakdown Data by Application
- 4.1 Global Preclinical Assets Historic Market Size by Application (2021-2026)
- 4.2 Global Preclinical Assets Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Preclinical Assets Market Perspective (2021-2032)
- 5.2 Global Preclinical Assets Growth Trends by Region
- 5.2.1 Global Preclinical Assets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Preclinical Assets Historic Market Size by Region (2021-2026)
- 5.2.3 Preclinical Assets Forecasted Market Size by Region (2027-2032)
- 5.3 Preclinical Assets Market Dynamics
- 5.3.1 Preclinical Assets Industry Trends
- 5.3.2 Preclinical Assets Market Drivers
- 5.3.3 Preclinical Assets Market Challenges
- 5.3.4 Preclinical Assets Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Preclinical Assets Players by Revenue
- 6.1.1 Global Top Preclinical Assets Players by Revenue (2021-2026)
- 6.1.2 Global Preclinical Assets Revenue Market Share by Players (2021-2026)
- 6.2 Global Preclinical Assets Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Preclinical Assets Head Office and Area Served
- 6.4 Global Preclinical Assets Players, Product Type & Application
- 6.5 Global Preclinical Assets Manufacturers Established Date
- 6.6 Global Preclinical Assets Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Preclinical Assets Market Size (2021-2032)
- 7.2 North America Preclinical Assets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Preclinical Assets Market Size by Country (2021-2026)
- 7.4 North America Preclinical Assets Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Preclinical Assets Market Size (2021-2032)
- 8.2 Europe Preclinical Assets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Preclinical Assets Market Size by Country (2021-2026)
- 8.4 Europe Preclinical Assets Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Preclinical Assets Market Size (2021-2032)
- 9.2 Asia-Pacific Preclinical Assets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Preclinical Assets Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Preclinical Assets Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Preclinical Assets Market Size (2021-2032)
- 10.2 South America Preclinical Assets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Preclinical Assets Market Size by Country (2021-2026)
- 10.4 South America Preclinical Assets Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Preclinical Assets Market Size (2021-2032)
- 11.2 Middle East & Africa Preclinical Assets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Preclinical Assets Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Preclinical Assets Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eurofins Scientific
- 12.1.1 Eurofins Scientific Company Information
- 12.1.2 Eurofins Scientific Business Overview
- 12.1.3 Eurofins Scientific Revenue in Preclinical Assets Business (2021-2026)
- 12.1.4 Eurofins Scientific Preclinical Assets Product Portfolio
- 12.1.5 Eurofins Scientific Recent Developments
- 12.2 Viroclinics Xplore
- 12.2.1 Viroclinics Xplore Company Information
- 12.2.2 Viroclinics Xplore Business Overview
- 12.2.3 Viroclinics Xplore Revenue in Preclinical Assets Business (2021-2026)
- 12.2.4 Viroclinics Xplore Preclinical Assets Product Portfolio
- 12.2.5 Viroclinics Xplore Recent Developments
- 12.3 SGS
- 12.3.1 SGS Company Information
- 12.3.2 SGS Business Overview
- 12.3.3 SGS Revenue in Preclinical Assets Business (2021-2026)
- 12.3.4 SGS Preclinical Assets Product Portfolio
- 12.3.5 SGS Recent Developments
- 12.4 Intertek Group
- 12.4.1 Intertek Group Company Information
- 12.4.2 Intertek Group Business Overview
- 12.4.3 Intertek Group Revenue in Preclinical Assets Business (2021-2026)
- 12.4.4 Intertek Group Preclinical Assets Product Portfolio
- 12.4.5 Intertek Group Recent Developments
- 12.5 AmplifyBio
- 12.5.1 AmplifyBio Company Information
- 12.5.2 AmplifyBio Business Overview
- 12.5.3 AmplifyBio Revenue in Preclinical Assets Business (2021-2026)
- 12.5.4 AmplifyBio Preclinical Assets Product Portfolio
- 12.5.5 AmplifyBio Recent Developments
- 12.6 IQVIA
- 12.6.1 IQVIA Company Information
- 12.6.2 IQVIA Business Overview
- 12.6.3 IQVIA Revenue in Preclinical Assets Business (2021-2026)
- 12.6.4 IQVIA Preclinical Assets Product Portfolio
- 12.6.5 IQVIA Recent Developments
- 12.7 ICON plc
- 12.7.1 ICON plc Company Information
- 12.7.2 ICON plc Business Overview
- 12.7.3 ICON plc Revenue in Preclinical Assets Business (2021-2026)
- 12.7.4 ICON plc Preclinical Assets Product Portfolio
- 12.7.5 ICON plc Recent Developments
- 12.8 Medpace
- 12.8.1 Medpace Company Information
- 12.8.2 Medpace Business Overview
- 12.8.3 Medpace Revenue in Preclinical Assets Business (2021-2026)
- 12.8.4 Medpace Preclinical Assets Product Portfolio
- 12.8.5 Medpace Recent Developments
- 12.9 Pharmatest Services
- 12.9.1 Pharmatest Services Company Information
- 12.9.2 Pharmatest Services Business Overview
- 12.9.3 Pharmatest Services Revenue in Preclinical Assets Business (2021-2026)
- 12.9.4 Pharmatest Services Preclinical Assets Product Portfolio
- 12.9.5 Pharmatest Services Recent Developments
- 12.10 PPD
- 12.10.1 PPD Company Information
- 12.10.2 PPD Business Overview
- 12.10.3 PPD Revenue in Preclinical Assets Business (2021-2026)
- 12.10.4 PPD Preclinical Assets Product Portfolio
- 12.10.5 PPD Recent Developments
- 12.11 Crown Bioscience
- 12.11.1 Crown Bioscience Company Information
- 12.11.2 Crown Bioscience Business Overview
- 12.11.3 Crown Bioscience Revenue in Preclinical Assets Business (2021-2026)
- 12.11.4 Crown Bioscience Preclinical Assets Product Portfolio
- 12.11.5 Crown Bioscience Recent Developments
- 12.12 Comparative Biosciences
- 12.12.1 Comparative Biosciences Company Information
- 12.12.2 Comparative Biosciences Business Overview
- 12.12.3 Comparative Biosciences Revenue in Preclinical Assets Business (2021-2026)
- 12.12.4 Comparative Biosciences Preclinical Assets Product Portfolio
- 12.12.5 Comparative Biosciences Recent Developments
- 12.13 TCG Lifesciences
- 12.13.1 TCG Lifesciences Company Information
- 12.13.2 TCG Lifesciences Business Overview
- 12.13.3 TCG Lifesciences Revenue in Preclinical Assets Business (2021-2026)
- 12.13.4 TCG Lifesciences Preclinical Assets Product Portfolio
- 12.13.5 TCG Lifesciences Recent Developments
- 12.14 Domainex
- 12.14.1 Domainex Company Information
- 12.14.2 Domainex Business Overview
- 12.14.3 Domainex Revenue in Preclinical Assets Business (2021-2026)
- 12.14.4 Domainex Preclinical Assets Product Portfolio
- 12.14.5 Domainex Recent Developments
- 12.15 Absorption Systems
- 12.15.1 Absorption Systems Company Information
- 12.15.2 Absorption Systems Business Overview
- 12.15.3 Absorption Systems Revenue in Preclinical Assets Business (2021-2026)
- 12.15.4 Absorption Systems Preclinical Assets Product Portfolio
- 12.15.5 Absorption Systems Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst